Questcor Pharmaceuticals (QCOR)
$4.28
0.03 (+0.71%)
| CAPS Rating |
|
|---|---|
| Open | $4.13 |
| Previous Close | $4.25 |
| Daily Range | $4.11 - $4.43 |
| 52-Week Range | $3.10 - $9.81 |
| Market Cap | $274.63M |
| P/E Ratio | 8.06 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 359,749 |
| Average Daily Volume | 779,000 |
QCOR
VS S&P 500 (SPY)
How do you think QCOR will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
QCOR Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
Related News and Articles
- A Mostly Meaningless FDA Approval – The Motley Fool
- Biotech Bargains for Your Portfolio – The Motley Fool
- 7 of the Most Efficient Companies on the Planet – The Motley Fool
- 5-Star Stocks Poised to Pop: Diageo – The Motley Fool
- 3 China Profit Plays – The Motley Fool
- A Big Upgrade for Amylin Pharmaceuticals – The Motley Fool
- Build Your Fortune With These Winners – The Motley Fool
- Still Enjoying Those Acquisitions, Pfizer? – The Motley Fool
- Novartis Didn't Know JAK, Until Now – The Motley Fool
- 12 Companies With Ironclad Balance Sheets – The Motley Fool
- 7 Dividend Divas – The Motley Fool
- A Schizophrenic Move by Merck? – The Motley Fool
- Do Good Without Being a Corporate Hotshot – The Motley Fool
- 52-Week Highs! What's Going On? – The Motley Fool
- 4 Platform Drugmakers to Invest In – The Motley Fool
- The Side Effect of Developing Obesity Drugs – The Motley Fool
- How I'm Grabbing 20% Dividend Yields – The Motley Fool
- Are These Dividends Too Good to Be True? – The Motley Fool
- This Baby Is a Nice Addition – The Motley Fool
- Now Is the Time to Buy Risk – The Motley Fool
RSS Headlines
Fool UK
